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1 These authors contributed equally to this work.The recommended treatment for patients with chronic hepatitis C, pegylated interferon a (PEG-IFN-
a) plus rebavirin (RBV), does not provide a sustained virologic response in all patients, especially
those with hepatitis C virus (HCV) genotype 1. It is therefore important to predict whether or not
a new patient with HCV genotype 1 will be cured by the recommended treatment. We propose a pre-
diction method for a new patient using a decision tree learning model based on SNPs evaluated in a
genome-wide association study. By the decision tree learning for 142 Japanese patients with HCV
genotype 1 (78 with null virologic response and 64 with virologic response), we can predict with
high probability (93%) whether or not a new patient with HCV will be helped by the recommended
treatment.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction [7–11]. Tanaka et al. reported that, within a Japanese populationChronic infection with hepatitis C virus (HCV) is a global health
problem affecting a signiﬁcant proportion of world’s population.
The World Health Organization estimated that in 1999 there were
170 million HCV carriers worldwide, with 3–4 million new cases
appearing each year [1,2]. A 48-week course of PEG-IFN-a with
RBV is the recommended treatment for patients with HCV involves,
but many patients will not be cured by it [3–5]. It also has side
effects that prevent some patients from completing therapy [6].
For these reasons, identiﬁcation of the determinants of responsive-
ness to the PEG-IFN-a with RBV treatment is a matter of high
priority.
Recent genome-wide association studies performed in order
to identify human genetic contributions to anti-HCV treatment
response have indicated that genetic polymorphisms near the
IL28B gene are associated with responses to HCV treatmental Societies. Published by Elsevier
S, genome-wide association
e minor genotype; MM, both
null virologic response; OR,
BV, ribavirin; SNPs, single
esponse
i), mmizokami@imcjk2.hosp.of patients with HCV genotype 1, those with minor alleles (TG
and GG) of SNP rs8099917 were more strongly associated with
null virological response (NVR) than were those with major
alleles (TT) (P = 2.65  1032) [7]. They also reported a logistic
regression model based on SNP, age, gender, re-treatment, plate-
let count, aminotransferase level, ﬁbrosis stage, and HCV-RNA
level indicated that rs8099917 is the most signiﬁcant factor for
NVR [7]. Ge and his colleagues reported not only that a genetic
polymorphism near the IL28B gene, encoding interferon-k-3
(IFN-k-3), is associated with an approximately twofold change
in responsiveness to treatment, both among African-American
patients (P = 2.06  103) and among patients of European ances-
try (P = 1.06  1026) but also that a polymorphism on chromo-
some 19, rs12979860, is strongly associated with sustained
virologic (SVR) in all patient groups (P = 1.37  1028) [8–10].
They also noted that their regression model showed that the
CC genotype is associated with a more substantial difference in
responsiveness rate than was any of the other known baseline
predictors included in the model. Suppiah et al. reported an
association to SVR within the gene region encoding interleukin
IL28B (rs8099917 combined P = 9.25  109, OR = 1.98, 95%
CI = 1.57–2.52) and indicated that host genetics may be useful
for predicting drug responsiveness [11].
The recent reports made clear that genetic polymorphisms near
the IL28B gene are associated with the responses of patients withB.V. Open access under CC BY-NC-ND license.
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indicated that predicting responsiveness to the treatment is an
urgent necessity. We therefore developed a new method for
predicting this responsiveness.
2. Materials and methods
Although the virological responses of patients with HCV geno-
type 1 to PEG-IFN-a with RBV have been reported to be strongly
associated with genetic polymorphisms, there is no report of
responsiveness being predicted from the polymorphisms. It is
quite important to know whether or not a new patient with HCV
genotype 1 will be cured by PEG-IFN-a with RBV before beginning
the treatment. Predicting patient’s responsiveness from the related
SNPs would help to reduce side effects and treatment costs.
The method we propose for predicting responsiveness uses
decision tree learning based on the genome-wide SNPs. Decision
tree learning is a method that uses inductive inference to approx-
imate a target function that will produce discrete values. It is gen-
erally best suited to problems in which instances are represented
by attribute-value pairs and the target function has discrete output
values. A decision tree classiﬁes each example into a class corre-
sponding to one of the output values [12].
2.1. Model for decision tree learning
Individual SNPs and their alleles (major, hetero, and minor
genotypes) in the genome-wide association study (GWAS) were
used as attributes. 142 Japanese HCV genotype 1 patients (64 with
virologic responses (VRs) and 78 with null virologic responses
(NVRs)) were used as training instances [7]. To carry out the super-
vised learning for their classiﬁcation, we partitioned the training
instances into two data sets: training data for growing the decision
tree, and testing data for pruning the decision tree. The classiﬁca-
tion processes were carried out in two phases: one for growing it
and the other for pruning it. We used the SLIQ/SPRINT algorithm
in the decision tree learning [13].
The SLIQ/SPRINT algorithm uses a two-branch (yes/no) ap-
proach, so for two combinations we selected the three types of
branches listed in Table 1. The previous analyses of genome-wide
drug responses for HCV genotype 1 patients indicated that speciﬁc
SNPs are closely associated with VRs/NVRs [7–11]. To analyze SNP
contributions to the drug effects, one ﬁrst needs to calculate an
evaluation function (such as the Gini diversity index (GDI)) for
three types of branches of individual SNPs and determine the max-
imum value of that function. Each SNP has three GDIs for individ-
ual alleles, and each GDI can be computed in the following way
[13]:
GDI ¼ 1
XK
l¼1
PðClÞ2 
XJ
m¼1
amð1
XK
l¼1
PðCmlÞ2Þ
am ¼ nmN ðm ¼ 1;2; :::; JÞ;
XJ
m¼1
am ¼ 1
ð1ÞTable 1
The three types of branches in the decision tree.
Type Combination 1 Combination 2
1 MM Het + mm
2 Het MM + mm
3 mm MM + Het
MM: both nucleotides are major genotypes (e.g., CC, C: major genotype).
Het: one nucleotide is a major genotype and the other is a minor genotype (e.g., TC,
T: minor genotype).
mm: both nucleotides are minor genotypes (e.g., TT).where K is the number of classes (in this case K = 2, VR and NVR),
P(Cl) is the probability of l class for each SNP in the instances, J is
a number of branches (J = 2 in the SLIQ/SPRINT algorithm), P(Cml)
is the probability of l class in the branch m, nm is a number of the
instances for the branch m, and N is the total number of the SNP
instances (in the ﬁrst case all instances are used, that is, N = 142).
2.2. Growth of the decision tree
A node is introduced for partitioning the instances in the deci-
sion tree, and in this article an SNP in the instances is used as a
node. The processes for growing the decision tree are, in outline,
as follows:
(1) The decision tree starts as a single node representing the HCV
patient instances.
(2) If the instances are all of the same class, the node becomes a
leaf and is labeled with that class.
(3) Otherwise, the attribute that will best separate the instances
into individual classes is selected by calculating the GDI for
each attribute. The node is labeled with this attribute.
(4) Two branches are created for the node attribute, and the
instances are partitioned accordingly.
(5) The same processes are carried out recursively to form a deci-
sion tree for the instances at each partition.
(6) The recursive partitioning stops only when one of the follow-
ing conditions is met:
 all instances for a given node belong to the same class, or
 there are no remaining attributes on which the instances
may be further partitioned.
2.3. Pruning of the decision tree
Working backward from the bottom of the tree, the subtree
starting at each non-terminal node is examined. If removing a sub-
tree improves the error (misclassiﬁcation) rate on the testing data,
the subtree is removed. This process continues until no further
improvement is made.
2.4. Prediction by decision tree learning
After completing the growth and pruning of the decision
tree, majority voting is carried out for individual leaves. That is,
the individual leaves are labeled with the most common classes
(VR and NVR) in the instances. In addition, VR and NVR classes
are assembled as the total VRs and NVRs for predicting VR and
NVR ratios.
The VR ratio predicted from the decision tree learning based on
the SNP information is given by
PVR ¼ DVRIVR ð2Þ
where DVR is the total number of VRs in the predicted VR class and
IVR is the number of VR instances.
The NVR ratio predicted from the decision tree learning is given
by
PNVR ¼ DNVRINVR ð3Þ
where DNVR is the total number of NVRs in the predicted NVR class
and INVR is the number of NVR instances.
The total number of VRs and NVRs predicted from the decision
tree learning is based on Eqs. (3) and (4) and is given by
PVRþNVR ¼ DVR þ DNVRAI ð4Þ
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That is, AI = IVR + INVR.
3. Results and discussion
One hundred and forty-two Japanese patients with HCV (78
NVR and 64 VR) receiving PEG-IFN-a/RBV treatment were ana-
lyzed by using the SNPs evaluated in a previous GWAS study [7].
Although a total of 621,220 SNPs were used for the genome-wide
association analysis, approximately 500 of those with the lowest
P-values calculated by using a v2 test for allele frequencies were
selected for the decision tree learning. Then GDIs were calculated
for three types of branches of individual SNPs selected. The node
with the largest GDI was selected as the root node of the decision
tree. In the ﬁrst case, GDI from rs8099917 was selected as the max-
imum branch node. That is, 142 Japanese HCV patients were di-
vided into two branches based on rs8099917. The growth of the
decision tree was carried out shown in Fig. 1, where one sees that
the ‘‘yes’’ and ‘‘no’’ branches from the root node B1 were, respec-
tively, Het + mm and MM. The numbers of instances in the two
branches divided by rs8099917 were, respectively, 65 in the
‘‘yes’’ branch and 77 in the ‘‘no’’ branch. As the most instances in
the ‘‘yes’’ branch node were NVRs (59 of 65, or 90.8%), this node
was labeled as the leaf node. From the descendent node on the
‘‘no’’ branch, a new descendant of the node was obtained using
the processes described in Section 2.2. After the decision tree
was grown, it was pruned as described in Section 2.3. The ﬁnal
form of the decision tree diagram is shown in Fig. 1.
The decision tree learning was carried out for the 142 Japanese
HCV patients with the 500 lowest-P SNPs, and the predicted VR
and NVR ratios were calculated using Eqs. (2) and (3):
PVR ¼ 48þ 764 ¼
55
64
¼ 0:859
PNVR ¼ 59þ 1478 ¼
73
78
¼ 0:936Fig. 1. Decision tree diagram for the treatment of Japanese HCV patients (78 NVR and
rs8099917). The bottom of the branch node shows the branch condition: left for ‘‘yes’’ and
is ‘‘no’’. B1, B2, and B3 are branch nodes and B1 is the root node. The numbers in the gree
the numbers of VR samples. The percentage next to each node shows the percentage o
(78 + 64) is 54.9%. The two circles in B2 and B3 indicate two ratios; the external one is the
node. In B2, for example, the external ratio shows that of B1 and the internal ratio indiThe predicted total number of VRs and NVRs was also calculated
using Eq. (4):
PVRþNVR ¼ 55þ 73142 ¼ 0:901
Before the decision tree learning by the SNP information, we knew
only that 64 of the Japanese HCV patients were VR for the drug re-
sponse and 78 were NVR. Therefore, all we can calculate is that the
VR and NVR response rates for those patients are respectively 0.451
(64/142) and 0.549 (78/142). After the decision tree learning, how-
ever, we can predict that the VR and NVR drug responses are respec-
tively 0.859 and 0.936 and can predict that the drug response rate
for the total 142 samples is 0.901 ((55 + 73)/142). This means that
if a new HCV genotype 1 patient wants to know whether or not
he/she is VR/NVR for the drug treatment, he/she can predict his/
her VR/NVR ratio by checking his/her SNP information in the deci-
sion tree shown in Fig. 1.
For example, suppose a new male HCV patient having
rs8099917, rs4906195, and rs3816768 alleles that are, respec-
tively, ‘‘MM’’, ‘‘Het’’, and ‘‘mm’’. In this case, it is predicted that
he will be VR for the recommended HCV drug treatment. On the
other hand, suppose a new female HCV patient having rs8099917
with ‘‘mm’’. In this case, it is predicted that she will mostly likely
be NVR for the recommended HCV drug treatment.
It is important to increase the prediction ratio in the decision
tree learning. The higher the prediction ratio, the better the drug
treatment response for a new HCV patient is predicted. In the deci-
sion tree model, the root node plays an important role in increasing
the prediction ratio. We therefore also generated decision tree
models by using root nodes based on the SNPs having the 30 high-
est GDIs. As a result, we got two decision trees that can predict
ratios higher than that of the ﬁrst decision tree. They are shown
in Figs. 2 and 3. The results of prediction ratios (probabilities pre-
dicted) for these decision tree models and the individual SNP attri-
butes used in the models are listed in Table 2. We got a 92.9%64 VR samples). The box at the top of a branch node indicates the SNP ID (e.g.,
right for ‘‘no’’. In the case of rs8099917, for example, ‘‘mm + Het’’ is ‘‘yes’’ and ‘‘MM’’
n parts of the nodes are the numbers of NVR samples, and those in the blue parts are
f the greater number of samples. In B1, for example, 78 is greater than 64 and 78/
ratio of the upper branch node and the internal one is the ratio of the present branch
cates that of node B2, i.e., 75.3% (58/(19 + 58)). L1, L2, L3, and L4 are leaf nodes.
Fig. 2. Diagram of model 2 decision tree. See legend to Fig. 1 for an explanation of symbols used.
Fig. 3. Diagram of model 3 decision tree. See legend to Fig. 1 for an explanation of symbols used.
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Table 2
Attribute SNPs in the three decision trees.
Model SNP used Probability predicted (%)
SNP P-value OR Chromosome Allele ratio (%)
1
rs8099917 3.11  1015 30 19 23.9
90.1rs4906195 4.52  104 3.9 14 18
rs3816768 2.85  104 4 15 16.4
2
rs6586361 7.81  105 5 1 17.3
92.3
rs6793110 2.82  104 10.7 3 5.7
rs12713624 1.56  104 3.8 2 33.1
rs10079121 1.11  103 3.1 5 25.7
rs1455474 2.96  104 4.6 8 47.9
rs315023 2.67  103 2.8 1 29.6
rs194507 3.19  104 3.5 7 34.4
3
rs4876271 2.3  105 4.5 8 27.8
92.9
rs11163027 1.51  104 4.7 1 12.7
rs1995122 1.98  104 4.1 6 14.8
rs7655238 3.21  103 3.4 4 46.1
rs12180485 5.16  103 2.8 6 17.6
rs1353348 1.36  104 3.9 15 35.1
rs1903998 2.58  103 3.1 10 40.5
P-value: v2 test for allele frequencies, OR: Odds ratio.
102 Y. Kawamura et al. / FEBS Open Bio 2 (2012) 98–102prediction probability with model 3. This is 2.8 percentage points
higher than that of model 1.
As the root node plays an important role, we examined what
chromosome the root node belongs to in each model. The chromo-
somes with individual root nodes in the models 1, 2, and 3 were,
respectively, 19, 1, and 8 (Table 2). Although SNPs near the IL28B
gene on chromosome 19 were recently reported to be the most sig-
niﬁcant factors, the root nodes in models 2 and 3 are on other chro-
mosomes. Other SNPs used in the models 2 and 3 are also on other
chromosomes (Table 2). These results therefore imply that there
may be signiﬁcant SNPs other than those near the IL28B gene on
chromosome 19.
Although that the virological responses of HCV patients treated
with PEG-IFN-a and RBV have been reported to be strongly associ-
ated with genetic polymorphisms, there is no report of what re-
sponses can be predicted from the polymorphisms [14]. If the
responsiveness of HCV patients to a drug treatment could be pre-
dicted from information about related SNPs, side effects and treat-
ment cost could be greatly reduced. Furthermore, because the
results of the proposed method implied that SNPs other than those
in the IL28B region are strongly related to the prediction of the
drug response, the relations between those SNPs and the drug re-
sponse should be examined experimentally.Acknowledgment
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